Caspofungin

Adult: 70 mg as loading dose on Day 1, followed by 50 mg once daily thereafter. In patients weighing >80 kg: 70 mg once daily. All doses are given via slow IV infusion over approx 1 hour. Treatment duration is based on clinical and microbiological response. Antifungal therapy should generally continue for at least 14 days after the last positive culture. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: 3 months to 17 years 70 mg/m² as loading dose on Day 1, followed by 50 mg/m² once daily thereafter. Dose may be increased to 70 mg/m² once daily if the lower dose is tolerated, but clinical response is inadequate. Max: 70 mg daily. All doses are given via slow IV infusion over approx 1 hour. Treatment duration is based on clinical and microbiological response. Antifungal therapy should generally continue for at least 14 days after the last positive culture. Treatment recommendations or approved starting age of use may vary among countries (refer to specific product guidelines).

Adult: For empiric treatment of presumed fungal infections: 70 mg as loading dose on Day 1, followed by 50 mg once daily thereafter. In patients weighing >80 kg: 70 mg once daily. All doses are given via slow IV infusion over approx 1 hour. Treatment duration is based on patient's clinical response. Continue empirical therapy until resolution of neutropenia. For patients found to have a fungal infection, treatment should be for at least 14 days and should continue for at least 7 days after neutropenia and clinical symptoms are resolved. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: 3 months to 17 years For empiric treatment of presumed fungal infections: 70 mg/m² as loading dose on Day 1, followed by 50 mg/m² once daily thereafter. Dose may be increased to 70 mg/m² once daily if the lower dose is tolerated, but clinical response is inadequate. Max: 70 mg daily. All doses are given via slow IV infusion over approx 1 hour. Treatment duration is based on patient's clinical response. Continue empirical therapy until resolution of neutropenia. For patients found to have a fungal infection, treatment should be for at least 14 days and should continue for at least 7 days after neutropenia and clinical symptoms are resolved. Treatment recommendations or approved starting age of use may vary among countries (refer to specific product guidelines).

Adult: In patients who are refractory to or intolerant of other therapies (e.g. amphotericin B, lipid formulations of amphotericin B, itraconazole): 70 mg as loading dose on Day 1, followed by 50 mg once daily thereafter. In patients weighing >80 kg: 70 mg once daily. All doses are given via slow IV infusion over approx 1 hour. Treatment duration is based on the severity of patient's underlying disease, clinical response, and recovery from immunosuppression. Dosage and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: 3 months to 17 years In patients who are refractory to or intolerant of other therapies (e.g. amphotericin B, lipid formulations of amphotericin B, itraconazole): 70 mg/m² as loading dose on Day 1, followed by 50 mg/m² once daily thereafter. Dose may be increased to 70 mg/m² once daily if the lower dose is tolerated, but clinical response is inadequate. Max: 70 mg daily. All doses are given via slow IV infusion over approx 1 hour. Treatment duration is based on the severity of patient's underlying disease, clinical response, and recovery from immunosuppression. Treatment recommendations or approved starting age of use may vary among countries (refer to specific product guidelines).

Adult: 50 mg once daily via slow IV infusion over approx 1 hour, continued for 7-14 days after resolution of symptoms. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Child: 3 months to 17 years 70 mg/m² as loading dose on Day 1, followed by 50 mg/m² once daily thereafter. Dose may be increased to 70 mg/m² once daily if the lower dose is tolerated, but clinical response is inadequate. Max: 70 mg daily. All doses are given via slow IV infusion over approx 1 hour. Continue treatment for 7-14 days after resolution of symptoms. Treatment recommendations or approved starting age of use may vary among countries (refer to specific product guidelines).